BioLife Solutions, Inc. (BLFS)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-30
$38.610.00%
Close 2026-10-07 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-30
Research Workspace
Put BLFS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Management is running behind on a stated commitment.
View ThesisMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 115% growth a year, above the roughly 21% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskBLFS depends on continued sales growth, despite unprofitable results and unsteady management. Revenue grew 21% year over year in Q2 FY2026, which beat on non-GAAP earnings. It trades at 18× sales versus a 3× peer median, with expectations pricing in more growth than forecast. The 21% next-quarter miss probability adds risk to those full expectations. Management is behind on a stated commitment. Peer multiples imply a price about 115% below where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-07. BLFS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 9 analysts currently covering BLFS (as of Oct 2026).
Based on 6 Wall Street analysts offering 12-month price targets for BLFS in the last 4 months.
Continue this research
Compare BLFS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BLFS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Supplies — fair value, gap to price, and forward P/E.
Compare the value case
Put BLFS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Complete acquisition by Repligen
Merger completion enhances growth potential significantly.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-07. EPS is implied from price ÷ P/E. Not investment advice.
Current $38.61
The last 12 months of price, then the range of analyst 12-month targets from today’s $38.61.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
